Your browser doesn't support javascript.
loading
In vivo anti-tumor activity of the PARP inhibitor niraparib in homologous recombination deficient and proficient ovarian carcinoma.
AlHilli, Mariam M; Becker, Marc A; Weroha, S John; Flatten, Karen S; Hurley, Rachel M; Harrell, Maria I; Oberg, Ann L; Maurer, Matt J; Hawthorne, Kieran M; Hou, Xiaonan; Harrington, Sean C; McKinstry, Sarah; Meng, X Wei; Wilcoxen, Keith M; Kalli, Kimberly R; Swisher, Elizabeth M; Kaufmann, Scott H; Haluska, Paul.
Affiliation
  • AlHilli MM; Division of Gynecologic Surgery, Department of Obstetrics and Gynecology, Mayo Clinic, Rochester, MN, United States.
  • Becker MA; Department of Oncology, Mayo Clinic, Rochester, MN, United States.
  • Weroha SJ; Department of Oncology, Mayo Clinic, Rochester, MN, United States. Electronic address: Weroha.Saravut@mayo.edu.
  • Flatten KS; Department of Oncology, Mayo Clinic, Rochester, MN, United States.
  • Hurley RM; Department of Oncology, Mayo Clinic, Rochester, MN, United States.
  • Harrell MI; Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Washington, Seattle, WA, United States.
  • Oberg AL; Division of Biomedical Statistics and Informatics, Department of Health Sciences Research, Mayo Clinic, Rochester, MN, United States.
  • Maurer MJ; Division of Biomedical Statistics and Informatics, Department of Health Sciences Research, Mayo Clinic, Rochester, MN, United States.
  • Hawthorne KM; Division of Biomedical Statistics and Informatics, Department of Health Sciences Research, Mayo Clinic, Rochester, MN, United States.
  • Hou X; Department of Oncology, Mayo Clinic, Rochester, MN, United States.
  • Harrington SC; Department of Oncology, Mayo Clinic, Rochester, MN, United States.
  • McKinstry S; Department of Oncology, Mayo Clinic, Rochester, MN, United States.
  • Meng XW; Department of Oncology, Mayo Clinic, Rochester, MN, United States.
  • Wilcoxen KM; TesaroBio, Inc, Waltham, MA, United States.
  • Kalli KR; Department of Oncology, Mayo Clinic, Rochester, MN, United States.
  • Swisher EM; Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Washington, Seattle, WA, United States.
  • Kaufmann SH; Department of Oncology, Mayo Clinic, Rochester, MN, United States; Department of Molecular Pharmacology & Experimental Therapeutics, Mayo Clinic, Rochester, MN 55905, United States.
  • Haluska P; Department of Oncology, Mayo Clinic, Rochester, MN, United States; Department of Molecular Pharmacology & Experimental Therapeutics, Mayo Clinic, Rochester, MN 55905, United States.
Gynecol Oncol ; 143(2): 379-388, 2016 Nov.
Article de En | MEDLINE | ID: mdl-27614696
Sujet(s)
Mots clés
Texte intégral
Ajouter à My VHL
Imprimer
XML
PubMed Links
Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Tumeurs de l'ovaire / Pipéridines / Recombinaison homologue / Inhibiteurs de poly(ADP-ribose) polymérases / Indazoles Type d'étude: Prognostic_studies Limites: Female / Humans Langue: En Journal: Gynecol Oncol Année: 2016 Type de document: Article Pays d'affiliation: États-Unis d'Amérique Pays de publication: États-Unis d'Amérique
Texte intégral
Ajouter à My VHL
Imprimer
XML
PubMed Links
Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Tumeurs de l'ovaire / Pipéridines / Recombinaison homologue / Inhibiteurs de poly(ADP-ribose) polymérases / Indazoles Type d'étude: Prognostic_studies Limites: Female / Humans Langue: En Journal: Gynecol Oncol Année: 2016 Type de document: Article Pays d'affiliation: États-Unis d'Amérique Pays de publication: États-Unis d'Amérique